Douglas S. Harrington, M.D.

Dr. Harrington has more than 25 years of experience in the commercialization of healthcare technology. Dr. Harrington currently holds senior management positions in a number of molecular diagnostics and device companies, including CEO of Aviir, Inc, a Stanford University spin-out biomarker company. Prior to 2008, he served as CEO and Lab Director at Specialty Laboratories, Inc. and WM Laboratories, Inc.; as Chairman and CEO of Chromavision Medical Systems, Inc.; and as President and Lab Director of Nichols Institute.

Dr. Harrington is licensed in a number of states, including New York, where he holds CQ’s in Molecular and Biochemical Genetics, and he has taken a number of new molecular technologies through state and federal regulatory approval. Dr. Harrington has been a board member of 14 companies, and he has multiple professional affiliation memberships including the American Medical Association, the American Society of Clinical Pathologists, the College of American Pathologists, The Association for Molecular Pathology, and the International Academy of Pathology. He has over 80 peer-reviewed publications. 
 
Current directorships and managerial positions in other companies include: Aviir, Inc (CEO and Board Member), Axela Biosensors (Board Member), Exiqon (Consulting Laboratory Director and Board Member), CLED (Chairman), and USC Keck School of Medicine (Clinical Associate Professor of Pathology).